No results for ‘’
Kerala Ayurveda Ltd
NSE: BSE: 530163
â‚ą173.65
(3.53%)
Mon, 14 Sept 2026, 06:56 pm
Market Cap (in Cr)226.37
PE Ratio0
Dividend0
Health Technology
Pharmaceuticals: Other
24.5KKerala Ayurveda Analysis
dividend
- Unable to evaluate Kerala Ayurveda's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Kerala Ayurveda's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Kerala Ayurveda is profitable, therefore cash runway is not a concern.
- Kerala Ayurveda is profitable, therefore cash runway is not a concern.
- Kerala Ayurveda had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
- Interest payments on debt are well covered by earnings (EBIT is 3.4x coverage).
- Kerala Ayurveda's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
- Debt is not well covered by operating cash flow (18.4%, less than 20% of total debt).
- Debt is not covered by short term assets, assets are 0.5x debt.
- Kerala Ayurveda's long term commitments exceed its cash and other short term assets.
- Kerala Ayurveda's level of debt (952.6%) compared to net worth is high (greater than 40%).
- High level of physical assets or inventory.
management
- Anilkumar's remuneration is about average for companies of similar size in India.
- Anilkumar's compensation has been consistent with company performance over the past year, both up more than 20%.
- The average tenure for the Kerala Ayurveda board of directors is less than 3 years, this suggests a new board.
misc
- Kerala Ayurveda is not covered by any analysts.
- Kerala Ayurveda has significant price volatility in the past 3 months.
past
- Kerala Ayurveda's 1-year earnings growth exceeds its 5-year average (83.8% vs 11.2%)
- Kerala Ayurveda's year on year earnings growth rate has been positive over the past 5 years.
- Kerala Ayurveda's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (83.8% vs 22.7%).
- Kerala Ayurveda used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Kerala Ayurveda's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
- Whilst Kerala Ayurveda made outstanding use of shareholders’ funds last year (Return on Equity greater than 40%), this is metric is skewed due to its high level of debt.
value
- Kerala Ayurveda's share price is below the future cash flow value, and at a moderate discount (> 20%).
- Kerala Ayurveda is good value based on earnings compared to the IN Pharmaceuticals industry average.
- 530163 outperformed the Market in India which returned -14.5% over the past year.
- BSE:530163 is up 53.2% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:530163 is up 53.2% outperforming the market in India which returned 8% over the past month.
- Kerala Ayurveda's share price is below the future cash flow value, but not at a substantial discount (< 40%).
- Kerala Ayurveda is overvalued based on assets compared to the IN Pharmaceuticals industry average.
- Kerala Ayurveda is overvalued based on earnings compared to the India market.
- 530163 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.